Symbols

CBIO

Crescent·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About CBIO

Crescent Biopharma, Inc.

A biotechnology company focusing on the development of new anti-tumor drugs

Industry

Biological Technology

Established Date

Listing Date

01/10/2014

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.glycomimetics.com

Security Type

Common stock

Office address

300 Fifth Avenue Waltham MA 02451

Business

Introduction

Crescent Biopharma, Inc., a Cayman Islands company incorporated in Delaware in 2003, is a late-stage clinical biotechnology company focused on improving the lives of patients with cancer and inflammatory diseases by inhibiting carbohydrate interactions that occur on the cell surface. The company is developing a proprietary pipeline of sugar mimics, small molecules that mimic the structure of carbohydrates and are involved in important biological processes that inhibit carbohydrate disease-related functions.

Company Financials

EPS

CBIO has released its 2025 Q4 earnings. EPS was reported at -3.35, versus the expected -2.47, missing expectations. The chart below visualizes how CBIO has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

CBIO has released its 2025 Q4 earnings report, with revenue of 10.84M, reflecting a YoY change of NaN%, and net profit of -92.40M, showing a YoY change of -506.44%. The Sankey diagram below clearly presents CBIO's revenue sources and cost distribution.